Nyxoah Enters New Chapter of Long Term Value Creation
Rhea-AI Summary
Nyxoah (Nasdaq: NYXH) announced a leadership transition process aimed at accelerating long-term value creation and U.S. commercial growth for its Genio system for Obstructive Sleep Apnea.
The Board has launched a search for a new U.S.-based CEO, while current CEO Olivier Taelman will remain fully engaged and lead daily operations during the transition.
Positive
- Board launches search for U.S.-based CEO focused on key growth market
- Current CEO remains in place to ensure operational continuity during transition
- Company highlights FDA PMA approval and IPOs as foundations for next phase
- Management cites strengthening U.S. commercial momentum for Genio system
Negative
- CEO transition process introduces leadership uncertainty until successor is appointed
- Lack of specified timeline for completion of the CEO search process
News Market Reaction – NYXH
In the Jun 5 session, NYXH declined 49.65%, reflecting a significant negative market reaction. Argus tracked a trough of -50.6% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 34.4x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Capital structure update | Neutral | +0.3% | Disclosure of new shares issued and updated capital and voting rights. |
| May 20 | Investor outreach | Positive | +0.3% | Investor federation visit following Q1 2026 results and U.S. momentum. |
| May 12 | Q1 2026 earnings | Positive | +0.3% | Strong revenue growth, especially in U.S., with updated 2026 guidance. |
| May 08 | Shareholder meetings call | Neutral | +2.1% | Invitation to annual and extraordinary meetings with governance agenda. |
| Apr 30 | Conference participation | Positive | +1.7% | Announcement of presentation at Bank of America 2026 Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news and earnings items over the last months produced modestly positive next-day reactions, indicating a history of relatively contained moves around corporate and financial updates.
Over the past months, Nyxoah has reported rising revenues and active corporate governance steps. Q1 2026 results showed expanding net revenue and ongoing U.S. Genio commercialization, followed by engagement with investors at LégiaPark and participation in a major healthcare conference. Capital structure updates, including new shares issued via a receivable contribution and an upcoming annual and extraordinary meeting on June 10, 2026, underscore continued financing and governance activity. Against this backdrop, the latest CEO transition announcement fits into a broader evolution toward U.S.-focused growth.
Key Terms
obstructive sleep apnea medical
osa medical
fda pma approval regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
INSIDE INFORMATION
REGULATED INFORMATION
Nyxoah Enters New Chapter of Long Term Value Creation
Commencement of process to transition to a U.S.-based CEO
Transition to support further acceleration of commercial Genio launch in the United States
Mont-Saint-Guibert, Belgium – June 4, 2026, 10:01 pm CET / 4:01 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the commencement of a leadership transition process in order to further accelerate the Company’s U.S. commercial traction.
Following seven successful years leading Nyxoah, Olivier Taelman, together with the Board of Directors, has decided that this is the right moment to transition leadership to a U.S.-based Chief Executive Officer as the Company enters its next phase of U.S.-driven growth and value creation. The Board has formally launched a search process to appoint a new U.S.-based CEO who will lead Nyxoah from within a critical market for the Company’s future growth.
Mr. Taelman will remain fully engaged during the transition period, continuing to lead the Company’s daily operations and to support a smooth onboarding and successful transition to the future CEO.
“Leading Nyxoah over the past seven years has been one of the most rewarding journeys of my professional career,” said Mr. Taelman. “Together with an exceptional team, we transformed Nyxoah from an early-stage clinical company into a global commercial medical technology platform with FDA PMA approval, successful IPOs on Euronext Brussels and Nasdaq, and a promising early commercial launch of Genio in the United States.”
Robert Taub, Chairman commented: “We appreciate Olivier Taelman’s outstanding contributions. The combination of strengthened financial resources, accelerating U.S. commercial momentum and a U.S.-focused leadership structure will position Nyxoah well for its next phase of growth in the rapidly expanding OSA market.”
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding its planned CEO transition; the Genio system; the potential advantages of the Genio system; and the Company's commercialization strategy and growth in the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
